ERBB2 and neoplasm: For example, HER2-positive breast cancer may impede the efficacy of HER2-targeted CAR-T cells due to the presence of antigen-negative tumor cells and a suppressive microenvironment that is abundant in regulatory T cells and PD-L1180.